Amphastar Pharmaceuticals AMPH EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's EPS (basic)?
- Amphastar Pharmaceuticals (AMPH) reported EPS (basic) of $0.14 in Q1 2026.
- How has Amphastar Pharmaceuticals's EPS (basic) changed year-over-year?
- Amphastar Pharmaceuticals's EPS (basic) decreased by 73.6% year-over-year, from $0.53 to $0.14.
- What is the long-term trend for Amphastar Pharmaceuticals's EPS (basic)?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's EPS (basic) has grown at a 12.7% compound annual growth rate (CAGR), from $1.30 to $2.10.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.